[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Nuformix Plc LSE:NFX London Ordinary Share GB00BYW79Y38 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.025 -2.13% 1.15 1.10 1.20 1.175 1.15 1.15 2,120,075 15:56:38
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Nonequity Investment Instruments 0.2 -1.4 -0.2 - 7

Nuformix Share Discussion Threads

Showing 7526 to 7548 of 7750 messages
Chat Pages: 310  309  308  307  306  305  304  303  302  301  300  299  Older
DateSubjectAuthorDiscuss
01/6/2021
07:58
JunkStillMonth away from better news Despite the gang pumping away
bigberty99
01/6/2021
07:26
Nuformix PLC 01 June 2021 Nuformix plc ("Nuformix" or the "Company") Project update Progress on pipeline assets NXP002 and NXP004 Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, confirms that, post-fund raising, it has started the planned studies on its pipeline assets NXP002 (new form of tranilast) and NXP004 (undisclosed oncology drug). -- NXP002 additional pre-clinical activities on inhalation feasibility data package commenced -- NXP004 additional research into new physical forms commenced NXP002 NXP002 is the Company's pre-clinical lead asset and a potential novel inhaled treatment for Idiopathic Pulmonary Fibrosis (IPF). It is a repurposed, new form of the drug tranilast, to be delivered in an inhaled formulation. As previously communicated, Nuformix planned to perform additional pre-clinical studies to generate a more robust data package with the goal of increasing the value of this asset and rendering it more attractive to licensing partners. Since completing the successful fundraise in March 2021, studies have commenced on these activities through outsourced expert contract organisations. NXP004 NXP004 represents novel forms of an undisclosed marketed oncology drug that has significant sales (more than GBP1 billion per annum in 2020) and is showing further growth. Nuformix filed one patent application on novel forms of this drug in 2020. Further outsourced research, through an expert contract organisation, on additional new forms and their properties has now commenced. If the research is positive, further patent applications may be filed. The third pipeline asset, NXP001, a new form of the drug aprepitant, is progressing as planned. Oxilio exercised an option to take a licence to the Intellectual Property on this asset for oncology indications on 23 March 2021 and the licence agreement is currently being progressed. Dr Anne Brindley, CEO of Nuformix, said: "I am pleased to communicate that, with the proceeds of the recent oversubscribed fund-raise in hand, the Company is executing on its plan that was communicated in March - both for NXP002 and NXP004. We are expecting results later in the year and further updates will be communicated when appropriate data are available. Thus, Nuformix is enacting on its strategy communicated in Q1 2021. Also the licensing discussions regarding NXP001 are ongoing and an update on that will be communicated at the appropriate time."
alancapone
26/5/2021
20:48
It seems that way. Revolving door has seen too many exits
carlisle44
26/5/2021
13:12
This is over !!
amaretto1
19/5/2021
09:39
Just for fun....https://www.griproom.com/fun/10-signs-your-company-is-about-to-be-acquired
dm2000
17/5/2021
13:54
Price action up. This indicates the seller is finished or has only a few more to go.
escapetohome
17/5/2021
13:16
berty, he had 17.7m shares over a week ago, there has been 40m+ volume since the time he notified.
soupdragon55
17/5/2021
12:46
Seller is here for a while
bigberty99
17/5/2021
12:28
250k and 500k still being dumped
bigberty99
17/5/2021
12:23
What it is the guy with 17m shares may have dumped 734k shares but they are speculating that he has dumped 17m in the last 3 days which is false. The pumpers will say anything to make u believe the seller is outWhy would a major holder be dumping in the first place.
bigberty99
17/5/2021
12:16
Major Holder's are dumping
georgeo1
11/5/2021
14:04
Took him nearly a month to notify surly he’s out now!!
spurs90
11/5/2021
14:01
7. Total positions of person(s) subject to the notification obligation % of voting rights attached to shares (total of 8. A) % of voting rights through financial instruments(total of 8.B 1 + 8.B 2) Total of both in % (8.A + 8.B) Total number of voting rights of issuervii Resulting situation on the date on which threshold was crossed or reached 3.24% 3.24% 591,609,368 Position of previous notification (if applicable) 4.73%
spurs90
10/5/2021
13:53
I'm interested in knowing where it was filed so that I know where it is actually protected.Further study of that patent shows international applications that appear to have already been granted in places such as EU, Australia, Japan and China. There is a WO application which I believe is a worldwide patent or PCT. This was filed in 2013 but does not yet have a grant date.The PCT (Patent Cooperation Treaty) seems to offer protection across a large number of countries and may therefore be the most significant.
for fx sake
10/5/2021
12:41
Spurs, it was already granted in 2018 in the US. The recent grant is Canada only. Hence no RNS.
soupdragon55
10/5/2021
12:07
Not really sure why you’re so hung up about where the patent was filed it does help if you read the information Description Tranilast Compositions and Cocrystals Cross Reference to Related Applications [001] This application claims priority to US Patent Application 61/618,639, filed March 30, 2012; the disclosure of which is incorporated herein by reference. Field of the Invention [002] The invention relates to new tranilast compositions and tranilast cocrystals. The invention also relates to therapeutic uses of the new tranilast compositions or cocrystals as well as pharmaceutical compositions containing them. Https://patents.google.com/patent/CA2908440C/en As per the Allenby report Expected NEWSFLOW Over the next 12-18 months there are a number of possible events on the horizon: – Initiation of the feasibility studies on NXP002 in Q2 2021- this is when we will hear about patent approval – OutcomedecisiononOxiliooptiononNXP001. – News on patent filing outcomes, strategic path and partnering for NXP004 in oncology. – Outcome of Innovate UK Grant Application for NXP002 in Q1 2021. – Potential completion (subject to funding) of Phase I ready package for NXP002 by H1 2022. – Partneringnewsacrossthepipeline. – Corporate: FY results 12 months ended 31 March 2021 – date estimated July/August. Http://www.allenbycapital.com/research_1168_68002803.pdf
spurs90
10/5/2021
09:56
A lot of twitteri people under water on this hence the pump
daar
10/5/2021
09:26
They didn’t fill my order @2.4p even though there were still some available before the spike. Good luck all, will keep watching. DC
daicaprice
10/5/2021
09:05
No quote online with HL, interesting. DC
daicaprice
10/5/2021
09:01
Thanks FFXS. DC
daicaprice
10/5/2021
08:34
A patent was finally granted for NXP002 on 20 April 2021 after being filed back in 2013.This was (as is usually the case) unearthed over the weekend by one of our vigilant posters (SoupDragon) over on the LSE board. The company obviously regards this as not newsworthy. Surprising really as I thought patents were effectively intangible assets which which are included in the values on the balance. The value must either already be factored in or it's worth zip.The patent appears to have been filed in Canada. Not sure why. I can understand the Ebers patents being filed there but not NXP002 Tranilast as well.
for fx sake
09/5/2021
23:10
What’s the story here please? Im Seeing patents awarded mentioned on twitter but no RNS. DC
daicaprice
27/4/2021
12:41
Bought in today, very low price ":^)
inthemix
Chat Pages: 310  309  308  307  306  305  304  303  302  301  300  299  Older
ADVFN Advertorial
Your Recent History
LSE
NFX
Nuformix
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211017 01:19:41